After a thrombectomy, for how many days should aspirin (81–100 mg daily) be continued together with clopidogrel (75 mg daily)?

Duration of Dual Antiplatelet Therapy After Thrombectomy

For patients with acute ischemic stroke treated with thrombectomy, dual antiplatelet therapy (aspirin 81–100 mg daily plus clopidogrel 75 mg daily) should be continued for exactly 21–30 days, then transitioned to single antiplatelet therapy indefinitely. This recommendation applies specifically to patients with minor stroke (NIHSS ≤3) or high-risk TIA who meet criteria for dual antiplatelet therapy (DAPT).

Patient Selection Criteria for DAPT After Thrombectomy

The decision to use DAPT depends on stroke severity and mechanism:

• DAPT is indicated for patients with minor ischemic stroke (NIHSS score 0–3) or high-risk TIA (ABCD2 score ≥4) of noncardioembolic origin 1, 2
• DAPT must be initiated within 24 hours of symptom onset (ideally within 12 hours) after intracranial hemorrhage has been excluded on neuroimaging 1, 2
• If thrombolysis was administered, antiplatelet therapy must be delayed until after the 24-hour post-treatment scan excludes intracranial hemorrhage 1, 3
• Patients with moderate-to-severe stroke (NIHSS >3) should receive aspirin monotherapy only, not DAPT, as the evidence base for DAPT does not extend to this population 2, 3

Loading and Maintenance Dosing Protocol

The specific dosing regimen is critical for optimal outcomes:

• Loading doses on Day 1: Clopidogrel 300–600 mg plus aspirin 160–325 mg 1, 2
• Maintenance therapy Days 2–21: Clopidogrel 75 mg daily plus aspirin 75–100 mg daily 1, 2
• After Day 21–30: Transition to single antiplatelet therapy with either aspirin 75–100 mg daily OR clopidogrel 75 mg daily, continued indefinitely 1, 2

The Canadian Stroke Best Practice guidelines specifically recommend 21–30 days of DAPT based on the CHANCE and POINT trials, which demonstrated that extending DAPT beyond 30 days significantly increases major hemorrhage risk (HR 2.32) without additional ischemic benefit 1.

Evidence Supporting the 21–30 Day Duration

The recommendation for this specific duration is based on high-quality randomized trial data:

• The POINT trial showed that 90 days of DAPT prevented 15 ischemic strokes per 1000 patients treated but caused 5 major hemorrhages per 1000 patients 1
• The CHANCE trial used 21 days of DAPT and demonstrated an 8.2% vs 11.7% stroke recurrence rate (HR 0.68) with acceptable bleeding risk 1
• Most stroke prevention occurs in the first week after the index event, with diminishing returns and increasing bleeding risk beyond 21–30 days 1, 2

The American Heart Association/American Stroke Association guidelines provide a Class 1, Level A recommendation for DAPT initiated early (within 12–24 hours) and continued for 21–90 days, but the Canadian guidelines have refined this to 21–30 days specifically to optimize the benefit-to-risk ratio 1.

Special Considerations for Thrombectomy Patients

For patients who underwent mechanical thrombectomy specifically:

• If carotid stenting was performed during thrombectomy for tandem occlusions, aspirin 250 mg IV may be administered during the procedure, with continuation of DAPT for the standard 21–30 day period 4
• Timing relative to thrombectomy: DAPT should be initiated as soon as possible after the procedure once hemorrhage is excluded, ideally before discharge from the emergency department 1
• If dysphagia is present: Aspirin 80 mg daily and clopidogrel 75 mg daily may be administered via enteral tube, or aspirin 325 mg daily via rectal suppository 1, 3

Transition to Long-Term Monotherapy

After completing 21–30 days of DAPT:

• Either aspirin OR clopidogrel may be used for long-term secondary prevention 1
• Aspirin 75–100 mg daily is the most commonly recommended option for indefinite continuation 1
• Clopidogrel 75 mg daily is an acceptable alternative, particularly in patients with aspirin intolerance 1
• Do not continue DAPT beyond 30 days unless there is a separate indication (such as recent coronary stenting), as bleeding risk outweighs benefit 1

Critical Pitfalls to Avoid

Several common errors can compromise outcomes:

• Never extend DAPT beyond 30 days in stroke patients without a compelling alternative indication, as the POINT trial demonstrated a 2.3-fold increase in major hemorrhage with 90-day DAPT 1
• Never initiate DAPT before 24 hours post-thrombolysis without repeat imaging confirming absence of hemorrhage 1, 3
• Never use DAPT in patients with NIHSS >3 after thrombectomy, as this population was not studied in the pivotal trials and should receive aspirin monotherapy only 2, 3
• Never use aspirin doses >100 mg daily during the maintenance phase of DAPT, as higher doses increase bleeding without improving efficacy 1, 5
• Never stop aspirin abruptly after discontinuing clopidogrel—transition to aspirin monotherapy should be seamless 1, 2

Bleeding Risk Monitoring

During the 21–30 day DAPT period:

• Monitor for signs of intracranial or systemic bleeding throughout the treatment period 2
• Consider gastroprotection with proton pump inhibitors in patients with gastrointestinal bleeding risk factors, though this may slightly reduce clopidogrel efficacy 6
• If major bleeding occurs, discontinue clopidogrel immediately and continue aspirin monotherapy only 1

The evidence strongly supports a fixed 21–30 day duration of DAPT after thrombectomy in appropriately selected patients with minor stroke or high-risk TIA, followed by indefinite aspirin monotherapy for secondary stroke prevention.